Basal cell carcinoma (BCC) is a very common malignant skin tumor that rarely metastatizes, even If Is often locally aggressive. Several factors, like large size (more than 3 cm), face localization, exposure to ultraviolet rays, histological variants, infiltration level and perineural or perivascular invasion, are associated with a more aggressive clinical course. In particular, the incidence of metastasis and/or death correlates with tumors greater than 3 cm in diameter in which setting patients are said to have 1--2 % risk of metastases that increases to 20--25% in lesions greater than 5 cm and to 50% in lesions greater than 10 cm in diameter ([@R12]). Histologically morpheiform, keratotic types and infiltrative growth of BCC are also considered features of the most aggressive course ([@R7]). This can be explained by the fact that both the superficial and nodular variants of BCC are surrounded by a continuous basement membrane zone comprising collagens type IV and V admixed with laminin, while the aggressive growth variants (i.e. morpheiform, metatypical, and infiltrative growth subtypes) manifest the absence of basement membrane ([@R2]).

The molecular markers which characterize aggressive BCC include: increased expression of stromolysin (MMP-3) and collagenase-1 (MMP-1) ([@R5]), decreased expression of syndecan-1 proteoglycan ([@R3]) and of anti-apoptotic protein bcl-2 ([@R11]; [@R13]).

C-ras , c-fos ([@R14]; [@R15]) and p53 tumor supressor gene mutations ([@R1]) are indicative of an aggressive course.

Focusing upon bcl-2 and p53 expression in BCC, there have been numerous studies documenting the utility of bcl-2 as a marker of favourable clinical behaviour while p53 expression may be a feature of a more aggressive outcome ([@R11]; [@R13]; [@R4]).

An increased expression of cytoskeletal microfilaments like α--smooth muscle actin, frequently found in invasive BCC subtypes ([@R9]), may explain an enhanced tumor mobility and deep tissue invasion through the stroma. ([@R6]; [@R10]). The aim of this preliminary study was to verify if also little (\<3 cm) basal cell carcinomas may express aggressive immunohistochemical markers like p53, Ki67 and alpha-SMA. We used 31 excisional BCCs with tumor size less than 2 cm (ranging from 2 up to 20 mm) and with different skin localization (19 in the face, 6 in the trunk and 6 in the body extremities). All cases were immunostained for p53, BCL2, Ki67 and alpha-smooth muscle actin (α-SMA) ([Table 1](#T1){ref-type="table"}). Immunoreactivity was evaluated by a semiquantitative score from 0 to 4, and interpreted by a two board-certified dermatopathologists (L.P. and C.M).

Table 1Clinical (age, sex, location, size), histological (histotype, depth infiltration in millimetre, ulceration, essudation and level of infiltration according anatomical skin layers URD upper reticular dermis; DRD deep reticular dermis ) and immunohistochemical data of 31 cases of BBC; essudation Mild=+; Moderate=++;Severe=+++; immunohistochemical score: 0= 0--6%; 1= 6--25%; 2= 25--50%; 3=51--75%;4=76--100%.*AgeSexLocationHystotypeMax.DimDepthUlcEssInfp53Bcl-2Ki67AML*161MExtrKeratotic10×81No+++URD+++++-261MFaceAdenoid10×94No+URD+++\-\--364MExtrSup mult11×130.8No+DRD+\-\--473MFaceNodular10×82Yes+DRD+++++++++584MFaceNodular9×122Yes+DRD\-\-\--684MFaceAdenoid50.8No+URD+++\-\--784MExtrNodular13×103No+DRD+++++-852FFaceNodular40.8No+URD+++-976FFaceAdenoid10×44No+DRD+++-++-1077FFaceMorph8×61Yes+++DRD+++\-\--1186MFaceMorph81Yes+DRD+++-++1263FFaceAdenoid41No+URD+++++1376FFaceNodular71.5No+DRD++++++-1484MFaceNodular114Yes+++DRD+\--+1563FFaceKeratotic10×61.8No++DRD-+++-1668FTrunkSup mult10×60.7No++URD++\--1767MFaceSup mult12×60.4No+URD+-+-1867MExtrSup mult4×30.3No+URD+++++-1932FExtrSup mult1×30.4No+URD+++-2045MTrunkNodular7×52Yes+++URD+++-2162MTrunkSup mult11×70.9No++URD-++-++2265MTrunkAdenoid7×61.5No+URD+++++-2372MTrunkNodular12×61No+URD+++-++2486FFaceKeratotic20×113.1No++DRD+++-2585MFaceNodular0.51.3No++DRD++++-2674FExtrNodular4×40.9No+URD\--+-2771MFaceNodular6×121.7No+DRD\--+-2864FTrunkSup mult1.3×1.50.4No++URD+++\-\--2978FFaceNodular4×31.5No++DRD+++-+++3080MFaceKeratotic4×41.6Yes+DRD\--++++

Table 2Comparison of our 8 α-SMA positive cases with negative cases.*LocationHistotypeLocal aggressivenessImmunohistochemistryFaceKeratoticMorpheiformDepht of invasion Mean value(mm)UlcerationInfiltration of the dermisP53Bcl-2Ki67*8 α-SMA Positive cases75%12%12%1.650%63%75%50%63%23 α-SMA Negative cases56%13%4%1.413%48%78%43%65%

Our data show that p53 (75%), Bcl2 (50%) and Ki67 (63%) positivity was generally diffuse in the majority of cases. On the contrary, cytoplasmatic α-SMA expression was present only in 8 out of 31 cases (25,8%). All these 8 α-SMA positive BCCs, prevalently found in the mideface (6 out of 8), were characterized by an initial invasion beyond the dermis. Among these 6 face-localized α-SMA positive BCCs, 1 showed a sclerosing aggressive histotype, 1 a keratotic type and 4 a nodular histotype.

These 8 little α-SMA-positive BCCs, compared to the others 23 α-SMA negative samples, all showed a major aggressiveness features: facial location, ulceration, morpheiform histotype and deeper infiltration into the dermis ([Table 2](#T2){ref-type="table"}). In particular, 75% of these α-SMA positive BCCs were localized in the midface; 24% presented with an aggressive histotype (keratotic and morpheiform); 50% showed ulceration; 63% tended to infiltrate the dermis deeply, with a mean depth of invasion of 1,6 mm ([Table 2](#T2){ref-type="table"}).

Given the absence of a specific difference between α-SMA positive cases and α-SMA negative cases in the expression of aggressive immunohistochemical markers, except for a light reduction of bcl-2 in the α-SMA positive group ([Table 2](#T2){ref-type="table"}), we focused our attention not only on the single marker but on the several possible immunohistochemical profiles that we could obtain ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). By the analysis of the data, we selected the combination that could better define an aggressive behaviour even for little BCC: α-SMA, p53, Ki67 positivity and bcl-2 negativity. We considered p53 and ki67 markers of proliferation and cell-cycle alteration, combined with a loss of apoptotic activity expressed by Bcl-2 negativity, quite characteristic of aggressiveness; moreover α-SMA positivity probably reflects invasive potential and acquired mobility by neoplastic cells.

This immunohistochemical profile (α-SMA, p53, Ki67 positivity and bcl-2 negativity) in our cases of BCC is present in two of them; one is a morpheiform BCC, that is an aggressive variant, while the other one is a nodular subtype (less aggressive).

Therefore, our preliminary data suggest that only α-SMA positivity should be considered as an early diagnostic marker of potential aggressiveness in little BCC: all α-SMA positive little BCC in fact showed clinical and histological features of aggressiveness. Invasive potential is probably acquired by some BCCs not only when they reach large size, but it is probably present also when they have still little size, and can be revealed by α-SMA positivity in the neoplastic cells.

Figure 1BCC, nodular type, HE, 10×.

Figure 2BCC, nodular type, α-SMA positivity, 10×.
